Cancer/Tumor Profiling Market Worth $13.9 Billion by 2025 - Exclusive Report by MarketsandMarkets™


2020-07-15 09:01:22 CISION


According to the new market research report "Cancer/Tumor Profiling Market by [Technology , Cancer Type ], Biomarker Type , Application, Region - Global Forecast to 2025", published by MarketsandMarkets™, the global Cancer Profiling Market size is projected to reach USD 13.9 billion by 2025 from USD 8.3 billion in 2020, at a CAGR of 10.9% during the forecast period. The increasing incidence of cancer across the globe and the growing use of biomarkers in tumor profiling are the primary growth drivers for this market. In addition, the increase in cancer research and funding initiatives and technological advancements in profiling technologies are also propelling the growth of the Tumor Profiling Market. The increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, the high capital investment required for biomarker discovery and the technical issues with sample collection and storage are the key factors restraining market growth to a certain extent. Download PDF Brochure: Due to the COVID-19 outbreak, there has been a significant drop in cancer testing and diagnosis due to measures and resources implemented towards coronavirus. However, several patients affected with COVID-19 were people with malignancies, due to which cancer has been identified as a risk factor for COVID-19. Research in this area is further undertaken to understand the dynamics of the infection better, which is expected to propel the cancer research field further. On the other hand, we are estimating that the major share of tumor diagnostic and prognostic testing of cancer, along with personalized medicine, will grow at a stable pace in the next five years. There is a huge deferment of treatment schedule of surgeries, radiation therapy, and chemotherapy sessions. Hence, the cancer treatment of surgeries, radiation therapy, and chemotherapy sessions should come to the levels of 2019 by the first quarter of 2021. By technology, the immunoassay segment is expected to account for the largest share of the Tumor Profiling Market Based on technology, the Cancer Profiling Market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share of 2019. These assays are used as a gold standard to conduct tumor profiling on a large scale as they help measure the presence and concentration of analytes in a sample. These tests are used for cancer diagnosis, prognosis, and treatment decisions. Moreover, the information gained by these tests in clinical settings helps shorten hospital stays and decrease the severity of illnesses by identifying and assessing the progression of the disease, leading to improved therapeutic choices. Browse in-depth TOC on "Cancer/Tumor Profiling Market" 242 – Tables 41 – Figures   302 – Pages Breast Cancer dominated the Cancer Profiling Market in 2019 Based on cancer type, the market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. The breast cancer segment accounted for the largest share in 2019 in Tumor Profiling Market, followed by lung cancer. The high prevalence of breast cancer across the globe is the major factor contributing to the large share of this segment. However, the lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing incidence of lung cancer worldwide and the rising need for early diagnosis are supporting the growth of this segment. The protein biomarker segment is expected to rise due to high adoption of proteomic methods for biomarker research to improve the drug development process during the forecast period Based on biomarker type, the market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. The protein biomarkers segment is estimated to grow at the highest CAGR of during the forecast period majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase the enormous potential for directing personalized cancer therapy and treatment monitoring. The research segment is the fastest-growing segment to increasing focus on biomarker discovery of drug development Based on applications, the Cancer/Tumor Profiling Market is segmented into research and clinical applications. The research applications segment accounted for the largest share of the Tumor Profiling Market in 2019. The increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine are expected to propel the growth of this segment. Additionally, the increased funding for cancer research is driving the growth of the market. Get 10% Customization on this Research Report: Asia Pacific to dominate the Cancer/Tumor Profiling Market during the forecast period Asia Pacific is estimated to be the largest market for market during the forecast period. The high-growth countries, such as China, India, South Korea, Australia, and Singapore, are the major contributors to the Asia Pacific Cancer Profiling Market. Asia Pacific is expected to be the fastest-growing regional market for cancer/tumor profiling majorly due to the high cancer incidence, growing proteomics and genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, growing awareness about personalized therapeutics, and increasing research activities in the field of mAb-based therapeutics in several APAC countries. The prominent players in this market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Roche Diagnostics(Switzerland). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Get Special Pricing on Bundle Reports: Browse Related Reports: Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022 Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022 About MarketsandMarkets™  MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact:Mr. Aashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Research Insight: Visit Our Website: Content Source: SOURCE MarketsandMarkets
根据 MarketsandMarkets ™发布的新市场研究报告“按[技术、癌症类型]、生物标志物类型、应用、区域-全球预测到2025年的癌症/肿瘤盈利市场”,到2025年,全球癌症盈利市场规模预计将从2020年的83亿美元增至139亿美元。在预测期内的复合年增长率为10.9%。 全球癌症发病率的不断上升以及生物标志物在肿瘤分析中的应用日益增多是该市场的主要增长动力。此外,癌症研究和资助计划的增加以及分析技术的技术进步也推动了肿瘤分析市场的发展。个性化医药需求的不断增长以及对点医疗诊断需求的不断增长,预计将在预测期内为市场参与者提供显著的增长机会。另一方面,生物标志物发现所需的高额资金投入和样本采集、存储的技术问题,在一定程度上制约了市场的增长。 下载 PDF 手册: 下载新。asp ?id =1250 由于 COVID-19的爆发,由于针对冠状病毒采取的措施和资源,癌症检测和诊断显著下降。然而,一些 COVID-19患者是恶性肿瘤患者,因此癌症已被确定为 COVID-19的危险因素。该领域的研究进一步深入,以更好地了解感染的动态,这有望进一步推动癌症研究领域的发展。另一方面,我们预计未来五年肿瘤诊断和预后检测在肿瘤诊断和预后检测中的主要份额,以及个性化用药将保持稳定增长。外科手术、放射治疗和化疗的治疗时间表有很大的延迟.因此,手术、放射治疗和化疗的癌症治疗应该在2021年第一季度达到2019年的水平。 根据技术,免疫分析部分预计将占肿瘤盈利市场的最大份额 基于技术,肿瘤图谱市场已细分为免疫检测、原位杂交、下一代测序( NGS )、聚合酶链反应( PCR )、质谱、微阵列等技术。免疫检测细分市场占2019年最大市场份额。这些检测方法被用作大规模进行肿瘤分析的金标准,因为它们有助于测量样本中分析物的存在和浓度。这些测试用于癌症诊断、预后和治疗决策。此外,这些测试在临床环境中获得的信息有助于缩短住院时间,并通过识别和评估疾病的进展来降低疾病的严重程度,从而改善治疗选择。 浏览「癌症/肿瘤市场」的深入 TOC 242-表格 41–数字 302–页面 乳腺癌在2019年占据了癌症盈利市场的主导地位 基于癌症类型,市场细分为乳腺癌、肺癌、结直肠癌、前列腺癌、黑色素瘤和其他癌症。乳腺癌细分市场在2019年肿瘤盈利市场中所占份额最大,其次是肺癌。在全球范围内,乳腺癌的高发病率是造成这一部分的主要因素。然而,肺癌部分预期于预测期内录得最高复合年增长率。全球肺癌发病率的增加和对早期诊断的需求的增加支持了这一部分的增长。 由于在预测期内生物标志物研究中大量采用蛋白质组学方法来改善药物研发过程,预计蛋白生物标志物细分市场将有所上升 基于生物标志物类型,市场细分为基因生物标志物、蛋白质生物标志物、其他生物标志物。蛋白质生物标记物分部预计在预测期内以最高复合年增长率增长,主要是由于生物标记物研究中越来越多地采用蛋白质组学的方法来改善药物研发过程。他们还展示了指导个性化癌症治疗和治疗监测的巨大潜力。 研究领域是增长最快的领域,越来越重视生物标志药物开发的发现 根据应用程序,癌症/肿瘤概况市场细分为研究和临床应用。研究应用分部于二零一九年占肿瘤盈利市场最大份额。随着个体化医疗领域的快速发展,人们越来越关注药物开发的生物标志物的发现,有望推动该领域的发展。此外,癌症研究经费的增加正在推动市场的增长。 获取本研究报告的10%自定义: New 。asp ?id =1250 在预测期内,亚太地区将主导癌症/肿瘤盈利市场 于预测期内,亚太区估计为最大市场。中国、印度、韩国、澳大利亚和新加坡等高增长国家是亚太地区癌症盈利市场的主要贡献者。由于癌症发病率高、蛋白质组学和基因组学研究不断增长、研究经费不断增加、制药和生物技术公司投资不断增加、对个性化治疗的认识不断提高,预计亚太地区将成为增长最快的癌症/肿瘤分析区域市场。以及在一些 APAC 国家增加基于 mAb 的治疗领域的研究活动。 该市场的主要参与者为 Illumina , Inc .(美国)、 QIAGEN N.V .(德国)、 NeoGenomics Laboratories , Inc .(美国)、 HTG 分子诊断公司(美国)、 Genomic Health Inc .(美国)、 Caris Life Sciences (美国)、 Helomics Corporation (美国)、 NanoString Technologies , Inc .(美国)、 Sysmex Corporation (日本)、罗氏(Roche) Diagnostics (瑞士)。 《周边市场:医疗器械市场研究报告与咨询》 获取捆绑报告的特殊定价: 。asp ?id =1250 查阅相关报告: 循环生物标志物、区域、最终用户、投资、市场动态、平台比较( NGS 、 PCR )、竞争格局(收购、合并、协作、竞争技术)的乳腺癌液体生物检测市场——2022全球预测。html 癌症生物标记物市场按类型(蛋白质生物标记物、基因生物标记物)、癌症类型(乳腺癌、黑色素瘤、白血病、肺癌)、盈利技术( Omics 、 Imaging 、 Immunoassay 、 Bioinformation )、应用(诊断、预后、研发)-全球预测至2022年肿瘤学生物标志物-202。html 关于 MarketsandMarkets ™ MarketsandMarkets ™提供针对30,000个高增长利基机会/威胁的量化 B2B 研究,这些机会/威胁将影响全球公司70%至80%的收入。目前为全球7500家客户提供服务,其中包括80%的全球财富1000强公司作为客户。全球八个行业的近75,000名高级管理人员通过 MarketsandMarkets ™了解他们在收入决策方面的痛点。 MarketsandMarkets ™的850名全职分析师和 SME 正在跟踪全球高增长市场,遵循“增长参与模型– GEM ”。创业板的目标是与客户积极合作,以确定新的机会,确定最重要的客户,制定“攻击,避免和捍卫”战略,为公司及其竞争对手确定增量收入来源。MarketsandMarkets ™现在每年在高增长的新兴细分市场上推出1,500个 MicroQuadrants (在领导者、新兴公司、创新者和战略参与者中定位顶级参与者)。MarketsandMarkets ™决心今年让1万多家公司受益于其收入规划,并通过提前向他们提供研究,帮助他们在市场早期进行创新/中断。 MarketsandMarkets 的旗舰竞争情报和市场研究平台“知识商店”将200,000多个市场和整个价值链连接起来,以便更深入地了解未得到满足的见解以及市场规模和利基市场预测。 联系方式: Aashish MehraMarketsandMarkets ™ INC.630 Dundee Road Suite 430Northbrook , IL 60062USA :+1-888-600-6441电子邮件:[电子邮件保护] Research Insight : Insight/Cancer-肿瘤型市场。asp 访问我们的网站: 内容来源: 。asp 股票市场和市场